Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 13Active not recruiting 3Completed 2Withdrawn 1No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Non-Small Cell Lung Cancer Metastatic 1Neoplasms 1

Interventions

pembrolizumab 382Carboplatin 279Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 242Cisplatin 217Paclitaxel 208Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 148atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102venetoclax 98fludarabine 97Radiosurgery 94Capecitabine 94Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × patritumab deruxtecan × 1 year × Clear all
NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Active not recruiting
277 enrolled 16 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT03260491 2026-03-05

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 1 Active not recruiting
312 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT04676477 2025-06-22

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 1 Active not recruiting
246 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡